Completed
Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
NCT01423110
- Conditions
- Muscular Diseases, Musculoskeletal Diseases, Myositis, +4 more
- Locations
-
- Novartis Investigative Site Scottsdale, Arizona, United States
- Novartis Investigative Site Kansas City, Kansas, United States
- Novartis Investigative Site Boston, Massachusetts, United States